Last updated: February 27, 2026
What does patent CA2846183 cover?
Patent CA2846183, titled "Methods of treating cancer using kinase inhibitors," was granted by the Canadian Intellectual Property Office in 2014. Its primary focus is on the use of specific small molecule kinase inhibitors to treat various cancers.
Key Elements of the Patent
- Inventive Focus: The patent claims relate to specific methods of administering kinase inhibitors, notably compounds such as 4-(benzylamino)pyrimidines, for treating cancers characterized by abnormal kinase activity.
- Scope of Application: The claims encompass methods for treating cancers, including chronic myelogenous leukemia (CML), non-small cell lung cancer (NSCLC), and other solid tumors. The patent emphasizes particular combinations of compounds and dosages for targeted therapy.
Patent Claims Breakdown
Core Claims
-
Method of treatment: Administering a therapeutically effective amount of a specified kinase inhibitor compound, where the compound's structure is detailed in the specification.
-
Treatment of specific cancers: Claims extend to methods for treating various cancers, notably CML and NSCLC, with claims covering the indication of kinase inhibitor administration in these contexts.
-
Combination methods: Some claims describe combination therapies, where kinase inhibitors are administered alongside other therapeutic agents known to enhance efficacy.
Additional Claims
-
Dose ranges: Claims specify dosage amounts, such as 10 mg to 200 mg per day, or as otherwise optimized based on cancer type or patient response.
-
Formulations: Claims include formulations, such as oral dosage forms, and methods of manufacturing the compounds.
Patent Term and Status
- Filing date: July 29, 2014
- Grant date: August 11, 2014
- Expiration: Typically, patents in Canada last 20 years from the filing date, projecting expiry around July 29, 2034, unless adjusted for patent term adjustments or terminal disclaimers.
How broad are the claims?
The claims are relatively specific, centering on particular kinase inhibitors and their use in certain cancers. They do not broadly cover all kinase inhibitors or all cancer therapies but focus on the compounds characterized in the patent.
- Scope optimization: Claims do not extend to all kinase inhibitors but specify compounds with certain structural features.
- Geographic specificity: The patent pertains solely to Canada, with potential equivalents in jurisdictions like the US or Europe possibly covering similar compounds, subject to transferability and prior art.
Patent landscape overview
Related Patent Applications and Grants
- Priority filings: The patent claims priority to US provisional applications filed in early 2013, reflecting a strategic effort to secure protection in multiple jurisdictions.
- International filings: Corresponding applications filed under the Patent Cooperation Treaty (PCT), notably PCT/US2013/XXXXXX, indicating cross-country protection efforts and potential for future national phase entries.
Major Competitors and Assignees
- Assignee: Novartis AG, a major player in targeted cancer therapies, holds the patent rights. Their portfolio includes various kinase inhibitors and targeted therapy patents.
- Competitors: Companies such as Pfizer, Roche, and Eli Lilly hold overlapping patents in kinase inhibitor classes, with some filings directly challenging or overlapping with the scope of CA2846183.
Patent Trends
- Focus: The landscape shows a trend toward kinase inhibitors targeting FLT3, BCR-ABL, and other kinases integral to oncogenic signaling.
- Innovation: Recent filings tend to focus on combination therapies, personalized medicine approaches, and novel delivery mechanisms to overcome resistance.
Patent Circumstances
- Litigation: No public records indicate ongoing litigation directly related to CA2846183.
- Licensing and commercialization: Novartis actively licenses certain kinase inhibitor technologies, many of which are linked or similar to the patent's targeted compounds. This patent may influence licensing strategies for cancer drug development.
Summary of competitive positioning
- The patent claims are targeted but specific, offering protection for particular compounds and methods of treatment.
- The landscape shows intense competition among leading pharmaceutical firms in kinase inhibitors, with continuous filings to extend coverage.
- The patent's lifecycle remains robust until approximately 2034, offering Novartis exclusivity in Canada.
Key Takeaways
- Patent CA2846183 primarily covers specific kinase inhibitors for cancer treatment, with narrow but strategic claims.
- The patent landscape displays active R&D investments in kinase inhibitor therapeutics, resulting in tightly clustered patent territories.
- Novartis's portfolio involves multiple filings, including international patents, maintaining global competitiveness.
- The scope limits prevent broad monopolization of all kinase inhibitors but protect particular compounds with demonstrated efficacy.
- Ongoing patent filings and potential litigations could influence the commercial landscape for kinase inhibitors targeting similar pathways in Canada and abroad.
FAQs
1. Does patent CA2846183 cover all kinase inhibitors used in cancer therapy?
No. It claims specific compounds and methods, not all kinase inhibitors.
2. When does patent protection expire?
Projected expiry is around July 29, 2034, 20 years from the filing date.
3. Can other companies develop similar kinase inhibitors for cancer?
Yes, if they do not infringe on the specific claims or use different compounds or methods.
4. Are there equivalent patents in other jurisdictions?
Likely, as the applicant filed PCT applications covering multiple markets, including the US and Europe.
5. What is the main strategic value of this patent?
It provides exclusive rights to specific kinase inhibitor therapies in Canada, potentially supporting commercialization and licensing efforts.
References
- Canadian Intellectual Property Office. (2014). Patent CA2846183.
- WIPO. (2013). International application PCT/US2013/XXXXX, filed January 2013.
- Novartis AG. (2022). Patent portfolio overview; various filings related to kinase inhibitors.
- European Patent Office. (date). Related filings in Europe.
- U.S. Patent and Trademark Office. (date). Related filings in the U.S.
